An observational study in Cervical Intraepithelial Neoplasia and Persistent Infection, sponsored by Xiamen University. Not yet recruiting at 3 sites in China. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Xiamen University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Uterine Cervical Dysplasia with a site in China — 11 open to participants now, 15 under way, 1 of them phase 3. Uterine Cervical Dysplasia · China.
Among the 56 studies in Uterine Cervical Dysplasia with a site in China, this one is the 10th largest by planned enrollment of the 22 observational ones that give a count, is the only one that started in 2027, is one of 22 observational ones, reaches primary completion later than 14 of the 14 other live ones, and was the 56th registered.
410 studies on the registry are indexed under Uterine Cervical Dysplasia; 76 are open to participants now.
Browse Uterine Cervical Dysplasia studies →11 of the 56 studies in Uterine Cervical Dysplasia with a site in China are open now. Recruiting first, the newest first:
Fujian Maternity and Child Health Hospital · Sites in China
Ages up to 45 · Women only
First Hospital of China Medical University · Sites in China
Ages 18–65 · Women only
Shanghai Zerun Biotechnology Co.,Ltd · Sites in China
Ages 12–34 · Women only · Healthy volunteers
Tongji Hospital · Sites in China
Ages 18–50 · Women only
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18 days+ · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 43 Uterine Cervical Dysplasia studies recruiting now, 19 (44%) set no upper age limit and 21 (49%) stop at 75 or younger; 3 take children under 18; 11 take healthy volunteers.
This study: female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2027.
This study's planned enrollment of 2,000 is above the median of 435 across 110 observational studies indexed under Uterine Cervical Dysplasia.
Median enrollment 330 across the 34 interventional studies, 1,270 across the 22 observational. Of the 18 that completed or were terminated, 5 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 56 have an industry lead sponsor. The 10 most frequent:
Xiamen University is the lead sponsor of 27 studies on the registry; 8 are open to participants now.
Xiamen University has 5 studies filed under Uterine Cervical Dysplasia — fewer than ten, so there is no comparison to draw.
2 of the studies in Uterine Cervical Dysplasia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07833852Shanghai Zerun Biotechnology Co.,LtdLong-Term Immune Persistence After Bivalent HPV Vaccination in Females From Study 311-HPV-1005 | 2026-12 |
| NCT06243666Xiamen UniversityLong-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 56 studies in Uterine Cervical Dysplasia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the long-term protection provided by a bivalent HPV vaccine produced in Escherichia coli against specific clinical endpoints related to HPV types 16 and 18 in women aged 18-45 years, as well as the persistence of antibodies specific to these two HPV types.
This observational study is a long-term follow-up of participants in the phase III clinical trial of a bivalent HPV 16/18 vaccine produced in Escherichia coli (HPV-PRO-003, NCT01735006). Women aged 18-45 years at enrollment in the original trial were randomly assigned to receive either the HPV vaccine or a hepatitis E vaccine. The follow-up study will retain the original vaccine and control groups. No additional study intervention will be administered.
Through 15 years after the first dose, this study aims to evaluate the long-term protection provided by the bivalent HPV vaccine against specific clinical endpoints associated with HPV types 16 and/or 18 and to assess the persistence of antibodies specific to HPV types 16 and 18.
The study population comprises women who received at least one dose of their assigned vaccine in the original phase III trial of the Escherichia coli-produced recombinant bivalent vaccine against human papillomavirus (HPV) types 16 and 18 (protocol HPV-PRO-003). To be eligible, women must not have received any HPV vaccine outside their original trial assignment since enrollment in that trial, including any subsequent catch-up doses given to control group participants. Participants retain their original group assignments (HPV vaccine group or hepatitis E vaccine control group).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women assigned to the vaccine group in the original phase III trial who received at least one dose of the bivalent HPV 16/18 vaccine. Since enrollment in the original trial, they must not have received any HPV vaccine other than the study vaccine administered as specified in that trial's protocol. Participants must also meet all other eligibility criteria for this follow-up study.
Biological: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
Women assigned to the control group in the original phase III trial who received at least one dose of control vaccine (hepatitis E vaccine). Since enrollment in the original trial, they must not have received any HPV vaccine other than vaccination specified in the original trial protocol. Participants must also meet all other eligibility criteria for this follow-up study.
The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
CIN2+, VIN2+, or VaIN2+ associated with HPV type 16 or 18 in the per-protocol population
This endpoint includes grade 2 or worse cervical, vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types
Time frame: At months 156 and 180 after the first dose in the original trial
6-month persistent infection with HPV type 16 or 18 in the per-protocol population
Infection with the same HPV type must persist for at least 6 months
Time frame: At months 156 and 180 after the first dose in the original trial
CIN1+, VIN1+, or VaIN1+ associated with HPV type 16 or 18
This endpoint includes grade 1 or worse cervical, vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types
Time frame: At months 156 and 180 after the first dose in the original trial
CIN2+ associated with HPV type 16 or 18
This endpoint includes grade 2 or worse cervical intraepithelial neoplasia associated with either or both HPV types
Time frame: At months 156 and 180 after the first dose in the original trial
VIN2+, or VaIN2+ associated with HPV type 16 or 18
This endpoint includes grade 2 or worse vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types
Time frame: At months 156 and 180 after the first dose in the original trial
HPV-16-specific infection and/or lesion endpoints
6-month persistent infection and grade 2 or worse cervical intraepithelial
Time frame: At months 156 and 180 after the first dose in the original trial
HPV-18-specific infection and/or lesion endpoints
6-month persistent infection and grade 2 or worse cervical intraepithelial
Time frame: At months 156 and 180 after the first dose in the original trial
Type-specific infection and/or lesion endpoints associated with other high-risk HPV types, including HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68
6-month persistent infection and grade 2 or worse cervical intraepithelial
Time frame: At months 156 and 180 after the first dose in the original trial
Type-specific seropositivity rates for HPV-16 and HPV-18 antibodies
Percentage of participants seropositive for HPV-16 and HPV-18 antibodies
Time frame: At months 156 and 180 after the first dose in the original trial
Type-specific HPV-16 and HPV-18 antibody levels
Serum antibody titers against HPV-16 and HPV-18
Time frame: At months 156 and 180 after the first dose in the original trial
incident HPV-16 and/or HPV-18 infection
Newly detected HPV-16 and/or HPV-18 DNA positivity
Time frame: At months 156 and 180 after the first dose in the original trial
Plan to share: Undecided — Proposals should be sent to the Principal Investigator. Proposals will be reviewed and approved by the study team.
Start is estimated for Jan 2027; primary completion for Dec 2029, 35 months later.
Of 44 observational studies under Uterine Cervical Dysplasia, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 30. This study's planned 35 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xiamen University